Most IDEs Now Include Patient Survey Data, US FDA Says
Executive Summary
The agency's ongoing focus on patient input is leading more sponsors to include patient-reported outcomes in pre-market studies, but FDA says it is continuing to look for ways to encourage the practice.
You may also be interested in...
Shuren: More Than A Dozen MDDTs Under Review, But No More This Year
The head of US FDA's device center says there are a substantial number of medical device development tools under review by the agency that could help speed up data collection for product approvals and clearances, but they are not likely to be OK'd by the agency until next year.
Patients Want Industry To Minimize Burdens, Augment Comforts Of Device Trial Participation
Patients and patient advocacy groups at the US FDA's inaugural Patient Engagement Advisory Committee meeting said they need sponsors to minimize the burdens and augment the comforts of trial participation, and get reports on outcomes along the way. Meanwhile, industry groups worried about revealing too much confidential business information, and biasing trial outcomes.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.